**Issues for the RCHC Data Standards and Integrity Council**

**June 29, 2020 Meeting**

Version 1, By Ben Fouts MPH, RCHC Data Analyst

1. **Follow-up From Last Meeting: Home Blood Pressure Check**

Report: Controlling High Blood Pressure

Issue: How are health centers documenting blood pressure readings taken at the patient’s home? Are there any data standards we can agree on around data entry?

Description: Last meeting, we discussed the difference between blood pressure readings taken at the health center versus those taken at the patient’s home. It was agreed that the main reporting agencies allow self-monitored blood pressures to be used for Quality Measures if the provider can visually see the measurement on the cuff during a virtual visit or if a cuff that is interfaced with the EHR submits blood pressure information.

The Council agreed that the blood pressure readings taken at home should be distinguished from those taken at the clinic. Council members were to return to the committee with information on if and how they are collecting and distinguishing the blood pressure data. This meeting, we will discuss a possible best practice and recommendations.

1. **Confirming Changes to the 2020 UDS and QIP Reports**

Report: UDS and Quality Measures (several reports)

Issue: We have discussed proposed changes to the UDS and QIP reports in previous Data Standards and Integrity Council (DSIC) meetings. The official instruction manuals have now been released, so this is a follow-up to those discussions.

If you have not downloaded the new instructions, here are the links:

UDS: <https://bphc.hrsa.gov/datareporting/reporting/index.html>

QIP: <http://www.partnershiphp.org/Providers/Quality/Pages/PCP-QIP-2020.aspx>

Description: For measures that changed, it is recommended that you compare and document the 2019 to the 2020 Relevant Quality Measures for the same measurement period now (for example, July 1, 2019 to June 30, 2020) and at the end of this year for the calendar year. You should also inform your quality care teams or others tracking the measures and set a specific date for switching over to the 2020 reports. At that point, you may also consider hiding the 2019 Quality Measures from view.

Although it is preferable to anticipate changes and discuss their impacts in the DSIC meetings, realistically, we always must wait until the final instructions are released. Page 73 of the 2020 Manual states, “BPHC requirements and guidance to be applied to the specific measure and that may differ from or expand on the eCQM specifications.”

Below are the conclusions to some of the issues previously discussed:

*January 6, 2020 DSIC meeting.* Controlling High Blood Pressure measure. The requirement for being first diagnosed with essential hypertension on June 30 or prior has been removed. A study done at the time found that across all RCHC health centers, the number of patients in the denominator increased by 9.4% and the measure numerator decreased by 1.4%.

|  |  |
| --- | --- |
| **2019** Measure description (UDS Manual, page 99) | **2020** Measure description (UDS Manual, page 100) |
| Patients 18 through 85 years of age who had a diagnosis of essential hypertension within the first six months of the measurement period or any time prior to the measurement period with a medical visit during the measurement period. | Patients 18 through 85 years of age who had a diagnosis of essential hypertension overlapping the measurement period with a medical visit during the measurement period. |

*March 2, 2020 DSIC meeting.* Discussion of potentially new UDS measures. These measures were actually NOT adopted. They were Diabetes Eye Exam, Diabetes Foot Exam and Caries Prevention by Primary Care Providers.

*May 4, 2020 DSIC meeting.* Discussion of potentially new QIP measures. One new measure (Well-Child Visits in the First 15 Months of Life) was adopted and one was not (Adolescent Well-Care Visits). The definition of another measure (Childhood Immunization Combo 10) was changed and now aligns with the UDS measure “Childhood Immunization Status.”

Other notable changes:

Childhood Immunization Status. Changed HIB vaccine from “three doses” to “three doses or four doses,” depending on the current guidelines of the manufacturer of the vaccine. There are different Value Sets for 3-dose and 4-dose HIB vaccines.

|  |  |
| --- | --- |
| **2019** Measure description (UDS Manual, page 79) | **2020** Measure description (UDS Manual, page 100) |
| …three H influenza type B (HiB)… | …three or four H influenza type B (HiB)… |

HIV Linkage to Care. Change to the follow-up treatment timeline from 90 days after initial diagnosis to 30 days.

|  |  |
| --- | --- |
| **2019** Measure description (UDS Manual, page 88) | **2020** Measure description (UDS Manual, page 88) |
| Newly diagnosed HIV patients that received treatment within 90 days of diagnosis. | Newly diagnosed HIV patients that received treatment within 30 days of diagnosis. |

Additional Information:

Here is a comparison of the 2020 UDS and QIP Measures. Bolded text indicates a new measure in 2020 for the respective report (see notes below). Measures in bold are new for that report in 2020.

| **2020 UDS Report** | **2020 QIP Report** |
| --- | --- |
| Early Entry into Prenatal Care |  - - |
| Childhood Immunization Status | Childhood Immunization Status (Combination 10) |
| Cervical Cancer Screening |  - - |
| ***Breast Cancer Screening*** |  - - |
| Colorectal Cancer Screening | Colorectal Cancer Screening |
| Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents |  - - |
| Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan |  - - |
| Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention |  - - |
| Statin Therapy for the Prevention and Treatment of Cardiovascular Disease |  - - |
| Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antiplatelet |  - - |
| HIV Linkage to Care |  - - |
| ***HIV Screening*** |  - - |
| Preventive Care and Screening: Screening for Depression and Follow-Up Plan |  - - |
| ***Depression Remission at Twelve Months*** |  - - |
| Dental Sealants for Children Between 6 – 9 Years |  - - |
| Controlling High Blood Pressure | Controlling High Blood Pressure |
| Diabetes: Hemoglobin A1c (HbA1c) Poor Control (> 9%) | Diabetes Management – HbA1c Good Control (≤9%) |
| - -  | Asthma Medication Ratio |
| - - | ***Well-Child Visits in the First 15 Months of Life*** |

Notes

* The 2020 UDS Breast Cancer Screening measure is the same as the 2019 QIP Breast Cancer Screening measure.
* The 2020 UDS Depression Remission at Twelve Months measure is the same as the 2019 ACO Depression Remission at Twelve Months measure.
* The 2020 UDS HIV Screening measure (CMS 349 v2) is completely new. A new QM will be created
* The 2020 QIP Well-Child Visits in the First 15 Months of Life measure is completely new. A new QM has already been made.
1. **Value Set Change for LDL Lab Tests**

Report: Statin Therapy for the Prevention and Treatment of Cardiovascular Disease

Issue: The OID number for LDL tests changed in the 2020 eCQM. This was the only detected change in the Value Set identification numbers.

Description: If you are using the Value Set OID to define the LDL labs, you will need to switch to the new identification number.

Additional Information:

2019: "Laboratory Test, Performed: LDL Test" using (2.16.840.1.113883.3.464.1003.198.11.1029)

2020: "Laboratory Test, Performed: LDL-c" using (2.16.840.1.113883.3.117.1.7.1.215)

|  |  |  |
| --- | --- | --- |
| **2019** | **2020** | **Value Set LOINC Description** |
| 12773-8 |  - -  | Cholesterol in LDL [Units/volume] in Serum or Plasma by Electrophoresis |
| 13457-7 | 13457-7 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation |
| 18261-8 | 18261-8 | Cholesterol in LDL [Mass/volume] in Serum or Plasma ultracentrifugate |
| 18262-6 | 18262-6 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay |
| 2089-1 | 2089-1 | Cholesterol in LDL [Mass/volume] in Serum or Plasma |
| 22748-8 |  - -  | Cholesterol in LDL [Moles/volume] in Serum or Plasma |
| 39469-2 |  - -  | Cholesterol in LDL [Moles/volume] in Serum or Plasma by calculation |
|  - -  | 43394-6 | Cholesterol in LDL acylated [Mass/volume] in Serum or Plasma |
| 49132-4 | 49132-4 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by Electrophoresis |
|  - -  | 50193-2 | Cholesterol in LDL.narrow density [Mass/volume] in Serum or Plasma |
| 55440-2 | 55440-2 | Cholesterol.in LDL (real) [Mass/volume] in Serum or Plasma by VAP |
|  - -  | 86911-5 | Cholesterol in LDL goal [Mass/volume] Serum or Plasma |
|  - - | 90364-1 | Cholesterol.in LDL.small dense [Mass/volume] in Serum by Immunoassay |
| - - | 91105-7 | Cholesterol in LDL 1 [Mass/volume] in Serum or Plasma |
|  - - | 91106-5 | Cholesterol in LDL 2 [Mass/volume] in Serum or Plasma |
|  - - | 91107-3 | Cholesterol in LDL 3 [Mass/volume] in Serum or Plasma |
|  - - | 91108-1 | Cholesterol in LDL 4 [Mass/volume] in Serum or Plasma |
|  - - | 91109-9 | Cholesterol in LDL 5 [Mass/volume] in Serum or Plasma |
|  - - | 91110-7 | Cholesterol in LDL 6 [Mass/volume] in Serum or Plasma |
|  - - | 91111-5 | Cholesterol in LDL 7 [Mass/volume] in Serum or Plasma |

1. **Keeping Outdated QIP Quality Measures**

Reports:

* Diabetes Management – Nephropathy Screening Test or Evidence of Nephropathy
* Diabetes Management – Retinal Eye Exam
* Well-Child Visits (3 – 6 Years Old)
* Immunizations for Adolescents

Issue: Are there any health centers that are interested in keeping these former QIP measures (2019)?

Description: If any health centers would like to keep following them, we can request that Relevant mark their QIP Value Sets as “current” (i.e., the most current ones) even though they are from 2019.

Additional Information: It might be a good idea to continue to follow these measures periodically through 2020. There may be a chance that QIP brings them back for 2021.